Balance Sheet
Cash Flow Statement
Cash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Change in Receivables (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Change in Receivables for 15 consecutive years, with -$2000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Receivables rose 50.0% year-over-year to -$2000.0, compared with a TTM value of -$2000.0 through Jun 2025, changed N/A, and an annual FY2024 reading of $4000.0, up 233.33% over the prior year.
  • Change in Receivables was -$2000.0 for Q3 2025 at Alaunos Therapeutics, up from -$3000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $2.9 million in Q3 2022 and bottomed at -$6.1 million in Q3 2021.
  • Average Change in Receivables over 5 years is -$291625.0, with a median of -$2500.0 recorded in 2025.
  • The sharpest move saw Change in Receivables plummeted 626.75% in 2022, then skyrocketed 400.0% in 2024.
  • Year by year, Change in Receivables stood at -$400000.0 in 2021, then tumbled by 626.75% to -$2.9 million in 2022, then surged by 100.03% to $1000.0 in 2023, then surged by 400.0% to $5000.0 in 2024, then crashed by 140.0% to -$2000.0 in 2025.
  • Business Quant data shows Change in Receivables for TCRT at -$2000.0 in Q3 2025, -$3000.0 in Q1 2025, and $5000.0 in Q4 2024.